These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 19017999

  • 1. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.
    Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S.
    J Immunol; 2008 Dec 01; 181(11):8068-76. PubMed ID: 19017999
    [Abstract] [Full Text] [Related]

  • 2. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration.
    Rohrer B, Long Q, Coughlin B, Wilson RB, Huang Y, Qiao F, Tang PH, Kunchithapautham K, Gilkeson GS, Tomlinson S.
    Invest Ophthalmol Vis Sci; 2009 Jul 01; 50(7):3056-64. PubMed ID: 19264882
    [Abstract] [Full Text] [Related]

  • 3. Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation.
    Atkinson C, He S, Morris K, Qiao F, Casey S, Goddard M, Tomlinson S.
    J Immunol; 2010 Dec 01; 185(11):7007-13. PubMed ID: 20962256
    [Abstract] [Full Text] [Related]

  • 4. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
    Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S.
    Arthritis Rheum; 2011 Apr 01; 63(4):1076-85. PubMed ID: 21452327
    [Abstract] [Full Text] [Related]

  • 5. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.
    Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S.
    J Clin Invest; 2005 Sep 01; 115(9):2444-53. PubMed ID: 16127466
    [Abstract] [Full Text] [Related]

  • 6. Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement.
    Alawieh A, Elvington A, Zhu H, Yu J, Kindy MS, Atkinson C, Tomlinson S.
    J Neuroinflammation; 2015 Dec 30; 12():247. PubMed ID: 26714866
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identifying the Role of Complement in Triggering Neuroinflammation after Traumatic Brain Injury.
    Alawieh A, Langley EF, Weber S, Adkins D, Tomlinson S.
    J Neurosci; 2018 Mar 07; 38(10):2519-2532. PubMed ID: 29437855
    [Abstract] [Full Text] [Related]

  • 11. In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries.
    Lei B, Sleiman MM, Cheng Q, Tu Z, Zhu P, Goddard M, Martins PN, Langerude L, Nadig S, Tomlinson S, Atkinson C.
    Front Immunol; 2021 Mar 07; 12():630581. PubMed ID: 34394069
    [Abstract] [Full Text] [Related]

  • 12. The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.
    Fridkis-Hareli M, Storek M, Or E, Altman R, Katti S, Sun F, Peng T, Hunter J, Johnson K, Wang Y, Lundberg AS, Mehta G, Banda NK, Michael Holers V.
    Mol Immunol; 2019 Jan 07; 105():150-164. PubMed ID: 30513451
    [Abstract] [Full Text] [Related]

  • 13. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
    Schmidt CQ, Harder MJ, Nichols EM, Hebecker M, Anliker M, Höchsmann B, Simmet T, Csincsi ÁI, Uzonyi B, Pappworth IY, Ricklin D, Lambris JD, Schrezenmeier H, Józsi M, Marchbank KJ.
    Immunobiology; 2016 Apr 07; 221(4):503-11. PubMed ID: 26792457
    [Abstract] [Full Text] [Related]

  • 14. Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization.
    Rohrer B, Coughlin B, Bandyopadhyay M, Holers VM.
    J Ocul Pharmacol Ther; 2012 Aug 07; 28(4):402-9. PubMed ID: 22309197
    [Abstract] [Full Text] [Related]

  • 15. The use of Matrigel combined with encapsulated cell technology to deliver a complement inhibitor in a mouse model of choroidal neovascularization.
    Annamalai B, Parsons N, Brandon C, Rohrer B.
    Mol Vis; 2020 Aug 07; 26():370-377. PubMed ID: 32476817
    [Abstract] [Full Text] [Related]

  • 16. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
    Michelfelder S, Fischer F, Wäldin A, Hörle KV, Pohl M, Parsons J, Reski R, Decker EL, Zipfel PF, Skerka C, Häffner K.
    J Am Soc Nephrol; 2018 Apr 07; 29(4):1141-1153. PubMed ID: 29335241
    [Abstract] [Full Text] [Related]

  • 17. A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice.
    He S, Atkinson C, Qiao F, Cianflone K, Chen X, Tomlinson S.
    J Clin Invest; 2009 Aug 07; 119(8):2304-16. PubMed ID: 19620784
    [Abstract] [Full Text] [Related]

  • 18. The alternative complement pathway propagates inflammation and injury in murine ischemic stroke.
    Elvington A, Atkinson C, Zhu H, Yu J, Takahashi K, Stahl GL, Kindy MS, Tomlinson S.
    J Immunol; 2012 Nov 01; 189(9):4640-7. PubMed ID: 23028050
    [Abstract] [Full Text] [Related]

  • 19. A novel complement inhibitor sMAP-FH targeting both the lectin and alternative complement pathways.
    Takasumi M, Omori T, Machida T, Ishida Y, Hayashi M, Suzuki T, Homma Y, Endo Y, Takahashi M, Ohira H, Fujita T, Sekine H.
    FASEB J; 2020 May 01; 34(5):6598-6612. PubMed ID: 32219899
    [Abstract] [Full Text] [Related]

  • 20. Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration.
    Annamalai B, Parsons N, Nicholson C, Joseph K, Coughlin B, Yang X, Jones BW, Tomlinson S, Rohrer B.
    Exp Eye Res; 2021 Jun 01; 207():108583. PubMed ID: 33878326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.